Related Experiment Video
Updated: Apr 11, 2026
11:49
Synthesis of Soft Polysiloxane-urea Elastomers for Intraocular Lens Application
Published on: March 8, 2019
13.3K
Viscoelastic interactions between polydeoxyribonucleotide and ophthalmic excipients
Iksoo Kim1, Hyeongmin Kim1, Kyunghee Park1
1a Pharmaceutical Formulation Design Laboratory , College of Pharmacy, Chung-Ang University , Seoul , Korea.
Drug Development and Industrial Pharmacy
|May 30, 2015
Summary
Polydeoxyribonucleotide (PDRN) interactions with ophthalmic excipients were studied. Nonionic agents like d-glucose and polymers such as HPMC are suitable for PDRN formulations, unlike ionic excipients.
Area of Science:
- Ophthalmology
- Pharmaceutics
- Materials Science
Background:
- Polydeoxyribonucleotide (PDRN) is utilized in ophthalmic preparations.
- Understanding excipient interactions is crucial for stable ophthalmic formulations.
Purpose of the Study:
- To investigate the rheological interactions between PDRN and various ophthalmic excipients.
- To determine the suitability of different excipients for PDRN-based ophthalmic formulations.
Main Methods:
- Rheological properties of PDRN solutions with individual excipients were analyzed.
- Dynamic oscillatory shear tests measured elastic modulus (G'), viscous modulus (G″), and loss tangent (tan δ).
Main Results:
- Ionic excipients, like sodium chloride, altered PDRN's viscoelastic properties.
- Nonionic isotonic agents (d-glucose, d-sorbitol) and nonionic polymers (PVP, HPMC) did not significantly interact with PDRN.
- Carbopol 940 showed interaction with PDRN.
Conclusions:
- PDRN interacts with ionic excipients, but interactions are negligible with nonionic excipients.
- Nonionic excipients are recommended for formulating with PDRN in ophthalmic preparations.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
245
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
245
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
777
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
777
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
125
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
125
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
228
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
228
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
221
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
221
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
872
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
872